Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Abbvie CDR ABBV


Primary Symbol: T.ABBV

Healthcare Drug Manufacturers - Major
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for...


TSX:ABBV - Post by User

Abbvie CDR
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
  • SmartBull65X
Post by SmartBull65on Dec 03, 2024 3:44pm
141 Views
Post# 36343644

ABBV: Botox Boost, But Humira’s Decline Looms 🧬

ABBV: Botox Boost, But Humira’s Decline Looms 🧬ABBV is solid for now, especially with Botox driving growth in aesthetics. But Humira’s revenue is dropping fast due to biosimilars. Rinvoq and Skyrizi are helping, but they still have big shoes to fill. Dividend looks strong, though. Also, keep an eye on $BOLT—people are talking about it potentially taking off!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities